TGFβ1-Selective Antibodies to Limit Cardiovascular Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TGFβ inhibitors face safety concerns due to dose-limiting toxicities such as cardiovascular abnormalities and are not effective in a broad range of cancer therapies, while existing cancer immunotherapies have limited efficacy and lack reliable biomarkers for patient selection.
Innovation Solution
Development of isoform-specific TGFβ inhibitors, such as TGFβ1-selective antibodies, and methods for monitoring circulating TGFβ and MDSC levels to guide treatment decisions, combined with checkpoint inhibitors and genotoxic therapies, to enhance therapeutic efficacy and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic TGFβ inhibition is used to treat cancer, then anti-tumor efficacy is improved, but cardiovascular toxicities and other dose-limiting adverse effects occur
Solution Approach 1:
The patent segments the TGFβ inhibition approach by developing isoform-specific inhibitors that selectively target TGFβ1 over TGFβ2 and TGFβ3. This segmentation allows differential inhibition of TGFβ isoforms, providing anti-tumor efficacy through TGFβ1 blockade while preserving the protective functions of TGFβ2 and TGFβ3 in cardiovascular tissues, thereby reducing cardiovascular toxicities
Solution Approach 2:
The patent applies local quality by creating inhibitors with selective affinity for specific TGFβ isoforms rather than pan-inhibition. The isoform-specific antibodies exhibit different binding characteristics toward TGFβ1, TGFβ2, and TGFβ3, enabling localized therapeutic effects in tumor microenvironments while maintaining normal physiological functions in healthy tissues through selective isoform preservation
2Adaptability or versatility
If pan-inhibition of all TGFβ isoforms is used, then broad anti-tumor activity is achieved, but safety profile deteriorates due to irreversible cardiovascular lesions
Solution Approach 1:
The patent divides the TGFβ inhibition strategy into isoform-specific components, developing antibodies that selectively target TGFβ1 while sparing TGFβ2 and TGFβ3. This segmentation enables the maintenance of broad anti-tumor activity through TGFβ1 blockade without the severe safety consequences of pan-inhibition, as TGFβ2 and TGFβ3 remain available to protect cardiovascular systems
Solution Approach 2:
The patent changes the selectivity parameter of TGFβ inhibition by designing isoform-specific antibodies with differential binding affinities. This parameter change from pan-inhibition to selective inhibition allows the therapy to maintain versatility against various tumor types while improving the safety profile by preventing irreversible cardiovascular lesions
3Reliability
If TGFβ inhibitors are developed to be isoform-specific, then safety is improved, but mechanism complexity increases due to targeting latent pro-protein complexes
Solution Approach 1:
The patent applies preliminary action by targeting the latent pro-TGFβ1 complex before it undergoes activation and processing. The isoform-specific antibodies bind to and inhibit the latent pro-protein complex, preventing the formation of active TGFβ1 and blocking downstream signaling. This preliminary intervention simplifies the therapeutic mechanism by addressing the upstream latent form rather than dealing with multiple activation pathways
Data Source
AI summary
The present disclosure provides TGFβ inhibitor therapy for treating immunosuppressive conditions, such as cancer. Methods of predicting and monitoring therapeutic response are disclosed. Related compositions, methods and therapeutic use are also disclosed.